UK Committee Wants Compulsory Licensing To Secure Cheap COVID-19 Products
ABPI Says Suggestion Is ‘Disappointing’
Executive Summary
Some way needs to be found to guarantee the supply of coronavirus products as more of them begin to become available, but the pharmaceutical industry says compulsory licensing is not the answer.
You may also be interested in...
‘Onshoring’ Not The Way To Tackle UK Coronavirus-Related Demand
A parliamentary committee has come up with some ideas for strengthening the UK’s response to future demand surges due to the spread of COVID-19.
EFPIA Rejects EU Calls To Relax IP Protections
State-imposed mechanisms such as compulsory licensing will discourage rather than encourage investment in R&D, says Europe’s research-based industry. It has also dismissed suggestions that Europe is too dependent on API supplies from third countries.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.